EMA Sets Elemental Impurities Implementation Dates
New drugs submitted for approval in Europe have 18 months to comply with new elemental impurities guidelines.
New drug products submitted for approval in Europe must comply with the new ICH Q3D Guidelines for Elemental Impurities, in June 2016. Existing products must comply in December 2017. The implementation dates set by the European Medicines Agency are earlier than those established by the US Pharmacopeial (USP) Convention.
In December 2014, ICH released the Step 4 version of ICH Q3D, Guidelines for Elemental Impurities, to regional standards organizations for implementation. The document stated that application of ICH Q3D to existing products was not expected prior to 36 months after publication.
On Jan. 15, 2015, USP announced plans to establish Jan. 1, 2018 as the new date of applicability of General Chapters <232> Elemental Impurities-Limits and <2232> Elemental Contaminants in Dietary Supplements. The date change was made to align more closely with implementation of ICH Q3D.
FDA has not announced implementation dates, but has listed a proposed guidance, Elemental Impurities in Drug Products Marketed in the United States, as a proposed new guidance for 2015.
Source: European Medicines Agency
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
